Get the Stockscreener App
8.5122
2.07%
-0.1778
Anavex Life Sciences Corporation stock is traded at $8.5122, with a volume of 425.47K.
It is down -2.07% in the last 24 hours and down -36.78% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
See More
Previous Close:
$8.69
Open:
$8.69
24h Volume:
425.47K
Relative Volume:
0.23
Market Cap:
$735.53M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-15.48
EPS:
-0.55
Net Cash Flow:
$-29.31M
1W Performance:
-8.20%
1M Performance:
-36.78%
6M Performance:
+39.97%
1Y Performance:
+52.24%
1-Day Range:
$8.446
$8.86
1-Week Range:
$8.446
$9.275
52-Week Range:
$3.25
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.51 | 735.53M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.46 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.17 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences (AVXL) to Release Quarterly Earnings on Wednesday - MarketBeat
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 - The Manila Times
Anavex Q1 2025 Earnings: Strategic Growth Updates Coming February 12 - StockTitan
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
JPMorgan Chase & Co. Acquires 1,191 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Receives "Buy" Rating from D. Boral Capital - MarketBeat
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’ - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital - Defense World
Anavex Life Sciences Secures New Patent For ANAVEX®2-73 - Evrim Ağacı
NASDAQ: AVXL Lawsuit Update: Investors Who Lost Money With Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) Should Contact the Shareholders Foundation - ACCESS Newswire
Anavex Life Sciences Secures New U.S. Patent For ANAVEX 2-73 Or Blarcamesine - RTTNews
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio - The Manila Times
Anavex Secures Crucial Patent for Alzheimer's Drug Delivery Breakthrough - StockTitan
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why - Nasdaq
Long-Term investors in shares of Anavex Life Sciences Corp. - openPR
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at HC Wainwright - Defense World
Best Momentum Stocks to Buy for January 21st - Yahoo Finance
New Strong Buy Stocks for January 21st - Yahoo Finance
SeaCrest Wealth Management LLC Invests $164,000 in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 9.4%What's Next? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 6.3%Time to Sell? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 9.4%Here's Why - MarketBeat
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease - The Manila Times
Anavex's Oral Alzheimer's Drug Shows Breakthrough 36% Disease Slowdown in Phase 3 Trial - StockTitan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Holdings Raised by Barclays PLC - MarketBeat
Barclays PLC Acquires 64,101 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Dru - Asianet Newsable
Anavex Life Sciences: Pioneering Precision Medicine for CNS Disorders - Big News Network
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from D. Boral Capital - MarketBeat
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients - The Manila Times
Anavex Life Sciences (NASDAQ:AVXL) vs. Pluri (NASDAQ:PLUR) Critical Comparison - Defense World
Playing The Odds Of Anavex Alzheimer's Drug Approval (NASDAQ:AVXL) - Seeking Alpha
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease - Seeking Alpha
Commit To Buy Anavex Life Sciences Corp At $7, Earn 28.6% Using Options - Nasdaq
Jane Street Group LLC Sells 119,531 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Jane Street Group LLC Trims Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 11.3%What's Next? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Trading 6.3% HigherStill a Buy? - MarketBeat
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Anavex Life Sciences to Present at JP Morgan Healthcare Conference 2025: Focus on Neurological Breakthroughs - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap UpShould You Buy? - MarketBeat
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
May 15 '24 |
Buy |
4.52 |
5,000 |
22,600 |
5,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Option Exercise |
1.32 |
73,380 |
96,862 |
1,323,590 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Sale |
5.11 |
73,380 |
374,972 |
1,250,210 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):